Therapies targeting HIF indirectly, such as vascular endothelial growth factor (VEGF) inhibitors, are the first-line treatments for ccRCC, but most patients develop drug resistance [17, 18]. The gene discussed is VEGFA; the disease is nonpapillary renal cell carcinoma.